journal
MENU ▼
Read by QxMD icon Read
search

Journal of Viral Hepatitis

journal
https://www.readbyqxmd.com/read/28429836/increased-levels-of-soluble-hla-g-molecules-in-tunisian-patients-with-chronic-hepatitis-b-infection
#1
Ahmed Baligh Laaribi, Daria Bortolotti, Naila Hannachi, Asma Mehri, Olfa Hazgui, Hamza Ben Yahia, Wafa Babay, Manel Belhadj, Houda Chaouech, Salwa Yacoub, Amel Letaief, Imene Ouzari, Abdellatif Boudabous, Dario Di Luca, Jalel Boukadida, Roberta Rizzo, Ines Zidi
Hepatitis B virus (HBV) infection is a global health problem. The mechanisms of immune tolerance in HBV infection are still unclear. The host immune response plays a critical role in determining the outcome of HBV infection. Human leukocyte antigen-G (HLA-G) is involved in immunotolerogenic process and infectious diseases. The present study aimed to explore the implication of soluble HLA-G (sHLA-G) and its isoforms in HBV infection. Total sHLA-G (including shedding HLA-G1 and HLA-G5) was analysed by ELISA in 95 chronic HBV patients, 83 spontaneously resolvers and 100 healthy controls...
April 21, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28419755/a-diagnostic-algorithm-for-assessment-of-liver-fibrosis-by-liver-stiffness-measurement-in-patients-with-chronic-hepatitis-b
#2
Yi-Jing Cai, Jia-Jia Dong, Xiao-Dong Wang, Si-Si Huang, Rui-Cong Chen, Yi Chen, Yu-Qun Wang, Mei Song, Yong-Ping Chen, Zhuo Li, Meng-Tao Zhou, Ke-Qing Shi
Steatosis could affect liver stiffness measurement in patients with nonalcoholic fatty liver disease and chronic hepatitis C. In the current study, we aimed to investigate the impact of steatosis on liver stiffness in chronic hepatitis B virus infected patients and develop a diagnostic algorithm for prediction of liver fibrosis by liver stiffness based on the controlled attenuation parameter. A total of 488 HBV infected patients who underwent clinical examination, FibroScan and liver biopsy were prospectively enrolled...
April 17, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28419653/hcv-viremia-associates-with-nk-cell-activation-and-dysfunction-in-anti-retroviral-hiv-hcv-co-infected-subjects
#3
E Papasavvas, L Azzoni, X Yin, Q Liu, J Joseph, A Mackiewicz, B Ross, K M Lynn, J M Jacobson, K Mounzer, J R Kostman, L J Montaner
The impact of Hepatitis C virus (HCV) RNA levels on immune status in chronically HCV mono-infected when compared to HIV/HCV co-infected on antiretroviral therapy (ART) remains poorly understood. A total of 78 African American subjects HCV viremic/naïve to HCV treatment (33 HCV genotype 1 mono-infected, 45 HCV genotype 1/HIV co-infected on ART) were studied. Clinical and liver enzymes measurements were performed. Whole blood was analyzed for immune subset changes by flow-cytometry. Peripheral blood mononuclear cells (PBMC) were used for same-day constitutive and in vitro Interferon (IFN)-α-induced Signal Transducer and Activator of Transcription (STAT) phosphorylation, K562 target cell lysis and K562 target cell recognition-mediated IFN-γ production...
April 17, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28414896/nk-cells-in-self-limited-hcv-infection-exhibit-a-more-extensively-differentiated-but-not-memory-like-repertoire
#4
Rik A de Groen, Zwier M A Groothuismink, Gertine van Oord, Neeltje A Kootstra, Harry L A Janssen, Maria Prins, Janke Schinkel, André Boonstra
Natural killer (NK) cells have long been thought of as a purely innate immune cell population, but increasing reports have described developmental and functional qualities of NK cells that are commonly associated with cells of the adaptive immune system. Of these features, the ability of NK cells to acquire functional qualities associated with immunological memory and continuous differentiation resulting in the formation of specific NK cell repertoires has recently been highlighted in viral infection settings...
April 17, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28414893/impact-of-viral-hepatitis-etiology-on-survival-outcomes-in-hepatocellular-carcinoma-a-large-multi-center-cohort-study
#5
Sara Mgaieth, William Kemp, Paul Gow, Michael Fink, John Lubel, Amanda Nicoll, Alessia Gazzola, Thai Hong, Marno Ryan, Virginia Knight, Anouk Dev, Siddharth Sood, Sally Bell, Eldho Paul, Stuart K Roberts
BACKGROUND AND AIMS: While HBV and HCV are risk factors for HCC, uncertainty exists as to whether these viral infections have prognostic significance in HCC. Thus, we compared the overall survival of patients with HBV, HCV, and non-viral HCC, and evaluated whether the presence of HBV and HCV predicts patient outcomes. METHODS: We conducted a multi-center study of HCC cases diagnosed at six Melbourne tertiary hospitals between Jan 2000-Dec 2014. Patient demographics, liver disease and tumor characteristics, and patient outcomes were obtained from hospital databases, computer records and the Victorian Death Registry...
April 17, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28375587/the-impact-of-hepatitis-b-virus-infection-and-vaccination-on-the-development-of-non-hodgkin-lymphoma
#6
Cih-En Huang, Yao-Hsu Yang, Yi-Yang Chen, Jung-Jung Chang, Ko-Jung Chen, Chang-Hsien Lu, Kuan-Der Lee, Pau-Chung Chen, Chih-Cheng Chen
BACKGROUND: Hepatitis B virus (HBV) infection has been documented as a risk factor for non-Hodgkin lymphoma (NHL). However, there are few large cohort studies, and there is no report about the impact of HBV vaccination. We conducted this study to evaluate these issues. METHODS: We used the nationwide cohort of the Taiwan National Health Insurance Research Database for 1997-2013. We compared the incidence and the risk of developing NHL and CD20(+) aggressive lymphoma between HBV and non-HBV cohorts...
April 4, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28370880/long-term-outcomes-of-daas-in-post-transplant-advanced-hcv-recurrence-and-fibrosing-cholestatic-hepatitis
#7
Ranka Vukotic, Fabio Conti, Stefano Fagiuoli, Maria Cristina Morelli, Luisa Pasulo, Maria Colpani, Francesco Giuseppe Foschi, Sonia Berardi, Paolo Pianta, Michele Mangano, Maria Francesca Donato, Federica Malinverno, Sara Monico, Mariarosa Tamè, Giuseppe Mazzella, Luca Saverio Belli, Raffaella Viganò, Paola Carrai, Patrizia Burra, Francesco Paolo Russo, Ilaria Lenci, Pierluigi Toniutto, Manuela Merli, Laura Loiacono, Rosamaria Iemmolo, Anna Maria Degli Antoni, Antonietta Romano, Antonio Picciotto, Maria Rendina, Pietro Andreone
Long-term functional outcomes of sofosbuvir-based antiviral treatment were evaluated in a cohort-study involving 16 Italian centers within the international compassionate-use program for post-transplant HCV-recurrence. Seventy-three patients with cirrhosis (n=52) or fibrosing cholestatic hepatitis (FCH, n=21) received 24-weeks sofosbuvir with ribavirin±pegylated interferon or interferon-free sofosbuvir-based regimen with daclatasvir/simeprevir+ribavirin. The patients were observed for a median time of 103 (82-112) weeks...
March 28, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28345206/treatment-with-direct-acting-antiviral-agents-of-hepatitis-c-virus-infection-in-injecting-drug-users-a-prospective-study
#8
Lucio Boglione, Simone Mornese Pinna, Amedeo De Nicolò, Jessica Cusato, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio
In this prospective study, we evaluated the effectiveness and tolerability of novel therapies against hepatitis C virus (HCV) in a cohort of PWID enrolled at our centre from April 2015 to July 2016. In this analysis, a total of 174 patients were included: 11 (6.3%) were treated with pegylated-interferon (PEG-IFN) and ribavirin (RBV) containing regimens, 163 (93.7%) with IFN-free treatments. RBV has been used in 70 patients (40.2%); 59 (33.9%) patients were in opioid substitution therapy (OST) with methadone or buprenorphine...
March 26, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28345157/entecavir-maleate-versus-entecavir-in-chinese-chronic-hepatitis-b-predominantly-genotype-b-or-c-results-at-week-144
#9
Jing-Hang Xu, Sa Wang, Zhong-Nan Xu, Yan-Yan Yu, Chong-Wen Si, Zheng Zeng, Jun Li, Mao Qing, Da-Zhi Zhang, Hong Tang, Ji-Fang Sheng, Xin-Yue Chen, Qin Ning, Guang-Feng Shi, Qing Xie, Xi-Quan Zhang, Jun Dai
Reports on the efficacy and safety of long-term entecavir treatment in chronic hepatitis B (CHB) predominantly genotype B or C are insufficient. This study presents the efficacy and safety of entecavir maleate in Chinese CHB patients. Patients were randomly assigned to receive 48-week treatment with either 0.5mg/day entecavir (group A) or 0.5mg/day entecavir maleate (group B), then all patients received treatment with 0.5mg/day entecavir maleate from week 49. Two hundred and seventy-five patients with CHB (HBeAg-positive: 218) were analyzed, predominantly (98...
March 26, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28342241/overt-and-occult-hepatitis-b-virus-infection-among-community-children-in-northwest-china
#10
H Su, Z Shao, Z Pu, Y Wang, L Zhang, W Zhang, B Wang, A Wang, Z Ji, Y Yan, Y Zhang
Although a universal newborn hepatitis B (HB) immunization programme has been implemented in China, hepatitis B virus (HBV) breakthrough infection, including HB surface antigen (HBsAg)-positive infection and occult HBV infection (OBI), still occurs during infancy or childhood. Obtaining the actual prevalence of HBV infection in general children is important for preventing and controlling the spread of HB. Accordingly, we investigated the prevalence of overt infection and OBI in community children and compared the serological and virological characteristics of OBI and HBsAg carrier children to clarify the mechanisms related to OBI...
March 25, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28342229/real-world-experience-with-the-all-oral-interferon-free-regimen-of-ombitasvir-paritaprevir-ritonavir-and-dasabuvir-for-the-treatment-of-chronic-hepatitis-c-virus-infection-in-the-german-hepatitis-c-registry
#11
Tania M Welzel, Holger Hinrichsen, Christoph Sarrazin, Peter Buggisch, Axel Baumgarten, Stefan Christensen, Thomas Berg, Stefan Mauss, Gerlinde Teuber, Kerstin Stein, Katja Deterding, Florian van Bömmel, Renate Heyne, Christine John, Tim Zimmermann, Thomas Lutz, Eckart Schott, Jan Hettinger, Henning Kleine, Bettina König, Dietrich Hüppe, Heiner Wedemeyer
Real-world studies are relevant to complement clinical trials on novel antiviral therapies against chronic hepatitis C, however clinical practice data are currently limited. This study investigated effectiveness and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) ± dasabuvir (DSV) ± ribavirin (RBV) for treatment of HCV genotype (GT) 1 and GT4 infection in a large real-world cohort. The German Hepatitis C Registry is an observational cohort study prospectively collecting clinical practice data on DAA therapies...
March 25, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28295923/effect-of-viral-suppression-on-hepatic-venous-pressure-gradient-in-hepatitis-c-with-cirrhosis-and-portal-hypertension
#12
N Afdhal, G T Everson, J L Calleja, G W McCaughan, J Bosch, D M Brainard, J G McHutchison, S De-Oertel, D An, M Charlton, K R Reddy, T Asselah, E Gane, M P Curry, X Forns
Portal hypertension is a predictor of liver-related clinical events and mortality in patients with hepatitis C and cirrhosis. The effect of interferon-free hepatitis C treatment on portal pressure is unknown. Fifty patients with Child-Pugh-Turcotte (CPT) A and B cirrhosis and portal hypertension (hepatic venous pressure gradient [HVPG] >6 mm Hg) were randomized to receive 48 weeks of open-label sofosbuvir plus ribavirin at Day 1 or after a 24-week observation period. The primary endpoint was sustained virologic response 12 weeks after therapy (SVR12) in patients who received ≥1 dose of treatment...
March 10, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28273410/cost-effectiveness-analysis-of-ledipasvir-sofosbuvir-in-patients-with-chronic-hepatitis-c-treatment-of-patients-with-absence-or-mild-fibrosis-compared-to-patients-with-advanced-fibrosis
#13
M Buti, R Domínguez-Hernández, I Oyagüez, M A Casado, R Esteban
To evaluate the cost-effectiveness of ledipasvir/sofosbuvir (LDV/SOF) in treatment-naïve patients with chronic hepatitis C (CHC) genotype 1 (GT1) in the absence or mild fibrosis (F0-F1) versus advanced fibrosis (F2-F4), from the perspective of the Spanish Health System. A Markov model was developed to simulate disease progression, estimating costs and outcomes [life years gained (LYG) and quality-adjusted life years (QALY)] derived from starting with LDV/SOF in patients with F0-F1 compared with F2-F4. Therapy duration was 8 weeks in noncirrhotic patients with viral load <6 million IU/mL and 12 weeks in the remaining patients...
March 8, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28273387/long-term-trends-in-chronic-hepatitis-b-virus-infection-associated-liver-transplantation-outcomes-in-the-united-states
#14
Kellie Young, Benny Liu, Taft Bhuket, Zobair Younossi, Sammy Saab, Aijaz Ahmed, Robert J Wong
With effective antiviral therapies, rates of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and decompensated liver disease requiring liver transplantation (LT) are expected to decrease. We aim to evaluate overall trends in LT waitlist registrations, waitlist survival, and likelihood of receiving LT among chronic HBV patients in the U.S. Using the United Network for Organ Sharing database, we retrospectively evaluated adults (age >18) with chronic HBV (with and without HCC) listed for LT from 1992-1996 (Era 1) vs...
March 8, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28273386/performance-of-the-pooled-cohort-atherosclerotic-cardiovascular-disease-risk-score-in-hepatitis-c-virus-infected-persons
#15
K W Chew, D Bhattacharya, T B Horwich, P Yan, K A McGinnis, C Tseng, M S Freiberg, J S Currier, A A Butt
Chronic hepatitis C virus (HCV) infection has been associated with an increased risk for cardiovascular disease (CVD). The recommended Pooled Cohort atherosclerotic cardiovascular disease (ASCVD) risk equation for estimation of 10-year CVD risk has not been validated in HCV-infected populations. We examined the performance of the ASCVD risk score in HCV-infected persons, using the national Electronically Retrieved Cohort of HCV Infected Veterans to derive a cohort of HCV-infected and uninfected subjects without baseline ASCVD, hepatitis B, or HIV infection, and with low-density lipoprotein cholesterol level<190 mg/dL...
March 8, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28267900/augmentation-of-hcv-specific-immunity-and-sustained-virological-response-svr
#16
Shikha Shrivastava, E Wilson, B Poonia, L Tang, A Osinusi, A Kohli, Shyam Kottilil
BACKGROUND: Treatment for chronic hepatitis C virus (HCV) infection has rapidly evolved into interferon-free directly acting antiviral regimens (DAA) that result in high sustained-virologic-response. DAAs primarily work by suppressing HCV replication and rely less on the immune system than interferon-based therapies. However it is unclear whether the immune system recovers with suppression of HCV replication and contributes to HCV clearance with DAA therapy. We previously demonstrated HCV clearance is associated with increased HCV-specific-immunity in CHCV-GT-1 infected patients during treatment with sofosbuvir (SOF)+ribavirin (RBV)...
March 7, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28256027/ongoing-incident-hepatitis-c-virus-infection-among-people-with-a-history-of-injecting-drug-use-in-an-australian-prison-setting-2005-2014-the-hits-p-study
#17
Evan B Cunningham, Behzad Harjarizadeh, Neil A Bretana, Janaki Amin, Brigid Betz-Stablein, Gregory J Dore, Fabio Luciani, Suzy Teutsch, Kate Dolan, Andrew R Lloyd, Jason Grebely
BACKGROUND: Hepatitis C virus (HCV) transmission is high in prisons. This study investigated trends in HCV incidence and associated factors among a cohort of prisoners with a history of injecting drug use in New South Wales, Australia. METHODS: Data were available from the Hepatitis C Incidence and Transmission Study in prisons (HITS-p) from 2005-2014. Temporal trends in HCV incidence were evaluated. Factors associated with time to HCV seroconversion among people with ongoing injecting was assessed using Cox proportional hazards...
March 3, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28248445/prevalence-and-distribution-of-hepatitis-c-virus-genotypes-in-spain-during-the-2000-2015-period-the-gehep-005-study
#18
Antonio Aguilera, Daniel Navarro, Francisco Rodríguez Frias, Isabel Viciana, Ana María Martínez-Sapiña, Mario José Rodríguez, Elisa Martró, María Del Carmen Lozano, Eleda Coletta, Laura Cardeñoso, Avelina Suárez, Matilde Trigo, Javier Rodríguez-Granjer, Natalia Montiel, Alberto de la Iglesia, Juan Carlos Alados, Cesar Vegas, Samuel Bernal, Felipe Fernández-Cuenca, María José Pena, Gabriel Reina, Silvia García-Bujalance, María Julia Echevarria, Laura Benítez, Sonia Pérez-Castro, Dolores Ocete, Isabel García-Arata, Carmen Guerrero, Manuel Rodríguez-Iglesias, Paz Casas, Federico García
AIM: We report the largest study on the prevalence and distribution of HCV genotypes in Spain (2000-2015), and we relate them with clinical, epidemiological and virological factors. METHODS: Patients from 29 hospitals in 10 autonomous communities (Andalusia, Aragon, Castilla-Leon, Catalonia, Galicia, Canary Islands, Madrid-Community, Valencian-Community, Murcia Region and Basque Country) have been studied. Annual distribution of HCV genotypes and subtypes, as well as gender, age, transmission route, HIV and/or HBV-coinfection, and treatment details were recorded...
March 1, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28218976/differential-expression-of-innate-immune-response-genes-in-clinical-phases-of-chronic-hepatitis-b-infection
#19
S Romani, S M Hosseini, S R Mohebbi, A Boonstra, A Sharifian
We investigated innate immune gene expression in clinical phases of chronic hepatitis B infection, including immune tolerant (IT), immune active (IA), inactive carrier (IC) and hepatitis B e antigen (HBeAg)-negative phases, as well as healthy controls. Expression levels of interferon types I, II and III, their receptor subunits, IRFs, TLRs and other IFN-induced genes in peripheral blood mononuclear cells were compared. Forty HBsAg-positive treatment-naïve subjects without co-infection with HIV, HCV or HDV were enrolled...
February 20, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28211256/endemic-prevalence-of-hepatitis-b-and-c-in-mongolia-a-nationwide-survey-among-mongolian-adults
#20
Bekhbold Dashtseren, Andreas Bungert, Purevjargal Bat-Ulzii, Maralmaa Enkhbat, Oyungerel Lkhagva-Ochir, Ganbolor Jargalsaikhan, Anir Enkhbat, Odgerel Oidovsambuu, Jane Klemen, Naranbaatar Dashdorj, Naranjargal Dashdorj, Zulkhuu Genden, Dahgwahdorj Yagaanbuyant
In this study a representative group of Mongolian adults was tested for hepatitis B virus (HBV) and hepatitis C virus (HCV). Screening was conducted at 17 different locations on a randomly sampled group, representative of the Mongolian adult population. A total of 1158 adults, 500 (43.1%) men and 659 (56.9%) women were included. The prevalence estimates of HBV and HCV among the general Mongolian adult population were found to be 11.1%± 1% (SE) and 8.5% ± 0.7% or 207,418 and 160,228 cases, respectively. For HCV the majority of cases are concentrated in older age groups with a prevalence of 25...
February 17, 2017: Journal of Viral Hepatitis
journal
journal
32017
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"